Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05005403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05005403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
November 1, 2021
Completion date
July 31, 2027
Enrollment
694 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

gastric/esophageal cancer, head and neck squamous cell carcinoma, high-grade serous ovarian cancer, micro satellite stable colorectal cancer, non-small cell lung cancer, pancreatic cancer, triple negative breast cancer